Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma.

Targeting" hepatitis C after liver transplantation.

Antiviral treatment with sofosbuvir and simeprevir in a kidney transplant recipient with HCV-decompensated cirrhosis: viral eradication and removal from the liver transplant waiting list.

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.

[Nanotechnology and nanomedicine: advances and promises for human health].

How hepatitis C virus modifies the immunological profile of SjĂśgren syndrome: analysis of 783 patients.

Characterization of a second secologanin synthase isoform producing both secologanin and secoxyloganin allows enhanced de novo assembly of a Catharanthus roseus transcriptome.

Hepatitis C treatment for patients post liver transplant.

Aplastic anemia and severe pancytopenia during treatment with peg-interferon, ribavirin and telaprevir for chronic hepatitis C.

Clinical trial watch: reports from the AASLD Liver MeetingÂŽ, Boston, November 2014.

Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation.

An experience of liver transplantation in Latin America: a medical center in Colombia.

The addition of a protease inhibitor increases the risk of infections in patients with hepatitis C-related cirrhosis.

HEV infection in two referral centers in Spain: epidemiology and clinical outcomes.

Valve-in-valve: estimating the risk of ostium obstruction in Sorin stentless valves.